Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD on Dr. Scholl’s

This article was originally published in The Tan Sheet

Executive Summary

A claim by Schering-Plough that Dr. Scholl's Dual Action Freeze Away Wart Remover "is twice as effective as freezing alone on large warts" is substantiated, according to the National Advertising Division. Schering submitted a study showing the product was twice as effective at resolving large warts as cryotherapy - a common medical treatment. NAD commented the case "represents a recent trend where advertisers tout the benefits of various cosmetic, topical or over-the-counter products as equivalent to or superior to medical procedures"...

You may also be interested in...



Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

Topics

UsernamePublicRestriction

Register

PS100280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel